EVALUATION OF CYTOTOXIC AND GENOTOXIC EFFECTS OF ZERUMBONE ON COLON ADENOCARCINOMA COLO205 CELLS AND HUMAN LYMPHOCYTES

RIMA THIYAM*, MANGAMOORI LAKSHMI NARASUb

**Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad 500085, Telangana, India

Received: 04 Jul 2017 Revised and Accepted: 21 Sep 2017

ABSTRACT

Objective: The objective of the present study was to investigate the growth inhibitory effect, apoptosis initiation and genotoxic activity of zerumbone, a phytochemical and cisplatin, a chemotherapeutic drug on human colorectal cancer cell line COLO205 and normal human lymphocytes.

Methods: The antiproliferative activity of zerumbone and cisplatin (positive control) on COLO205 cells and lymphocytes was analysed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological analysis of the cells was studied by using an inverted phase contrast microscope. Propidium iodide staining method was used to observe the apoptotic morphological changes in the treated cells. Finally, comet assay was conducted to observe the extent of DNA damage induced by zerumbone and cisplatin on COLO205 and lymphocytes.

Results: Zerumbone and cisplatin exhibited growth inhibition in a dosedependent manner against COLO205 with not much considerable effect on lymphocytes. The IC50 values of zerumbone and cisplatin COLO205 for 24h, 48h and 72h were 19µg/ml, 10 µg/ml, 5 µg/ml and 38 µg/ml, 24 µg/ml, 15 µg/ml respectively. Morphological changes such as cell shrinkage, membrane blebbing and nuclear condensation were observed in COLO205 while more prominent change was not observed in lymphocytes. Fluorescence imaging studies confirmed apoptotic cell death in treated COLO205 cells while cell death was not clearly observed in treated lymphocytes. Comet assay revealed significant DNA damage in treated COLO205 cells.

Conclusion: The present study demonstrated the cytotoxic and genotoxic effects of zerumbone on colon cancer cells with minimal effect on normal lymphocytes. The results of the study have revealed that zerumbone can be used as an effective therapeutic drug in treating colon cancer.

Keywords: Zerumbone, Cisplatin, COLO205, Lymphocytes, MTT assay, Comet assay

INTRODUCTION

Plant-derived compounds are most commonly used as medicines in the world today. Every culture on Earth, through written or oral tradition, has relied on the huge variety of natural products found in healing plants for their curative properties. One-fourth of modern drugs prescribed worldwide are plant-derived, where 12% of these bioactive compounds are currently used in the treatment of various ailments [1]. Natural phytochemicals hold a great promise in clinical therapy as they possess no side effects that are usually associated with chemotherapy or radiotherapy. They are also comparatively inexpensive as they are ubiquitous and thus significantly reduce health care cost. Phytochemicals are the plant compounds with specific biological activities that support human health [2].

Zerumbone is a phytochemical, present in the rhizomes of Zingiber zerumbet Smith and Zingiberaromaticum [3]. Its molecular formula is C15H23O2. The IUPAC name of this phytochemical is (2E, 6E, 10OE)-6, 9, 9-tetramethyl cycloundeca-2, 6, 10-trien-1-one [4]. It was found to possess many biomedical properties such as antioxidant, anti-inflammatory and antimicrobial activities [5,6]. It has been proven to possess anti-cancer, immunomodulatory and apoptosis-inducing properties against various human tumour cells, but with least effect on normal cells [7-11].

A variety of in vitro genotoxicity test systems have been developed in the cultured mammalian cell systems such as human peripheral blood lymphocytes for the screening of potentially cytotoxic, mutagenic and carcinogenic agents [12-14]. According to the literature survey, there exists a lack of good basic information about the genotoxic potential of zerumbone on colon cancer cells. In this context, the present work has been carried out to study the genotoxic potential of zerumbone on human colorectal cancer cell line, COLO205 and human peripheral blood lymphocytes. The current work can be seen as the comparative analysis of zerumbone genotoxicity activity against the COLO205 cells and lymphocytes, as well the cell growth inhibition and apoptosis induction by zerumbone in COLO205 cells and lymphocytes were studied.

MATERIALS AND METHODS

Chemicals

Zerumbone, cisplatin, lymphocyte isolation medium (Histopaque 1077), MTT and propidium iodide were purchased from Sigma Aldrich (St. Louis, MO, USA). Fetal bovine serum, RPMI 1640, trypsin and dimethyl sulfoxide (DMSO) were procured from HiMedia (Mumbai, India). All other chemicals and reagents used in this study were of analytical or HPLC grade and obtained from Sigma Aldrich (St. Louis, MO, USA) and Himedia (Mumbai, India).

Cell culture and maintenance

Human colorectal cancer cell line, COLO205 was obtained from National Centre for Cell Science, Pune (India). Cells were cultured in RPMI 1640 supplemented with 10%fetal bovine serum, penicillin (100 IIU/ml) and streptomycin (100µg/ml) at 37 °C in a humidified incubator with 5% CO2 atmosphere. Once the cells reached ~90%confluency, they were trypsinized, washed thoroughly with media and subcultured into a new 25cm2 culture flask for expansion.

Isolation of peripheral blood lymphocytes

Peripheral blood was aseptically collected from healthy, non-smoking donors (below 30 y) by venepuncture into preservative-free EDTA tubes. The blood was diluted by adding phosphate buffered saline (PBS), pH 7.4 and carefully layered onto Histopaque 1077, centrifuged at 400 x g for 30 min, at interface lymphocytes were suspended. Trypan blue exclusion was used to assess the viability of isolated lymphocytes and the viability of these cells was found to be above 90%. The final concentration of lymphocytes was adjusted to about 2x106 cells/ml.
Anti-proliferative activity of zerumbone and cisplatin

The MTT assay was performed to study the antiproliferative effect of zerumbone and cisplatin on COLO205 and lymphocytes. Cells were treated with varying concentrations (0-100 µg/ml) of zerumbone and cisplatin for different time intervals (24h, 48h, 72h) at 37 °C, 5% CO₂ along with the untreated control samples (which contained an equivalent concentration of DMSO). After every incubation period, cells were washed with PBS, treated with MTT and again incubated for 4h after which MTT was removed, then DMSO was added and finally, the plate was read at 540 nm in an EUSA plate reader. The data were represented as the percent post-treatment recovery (% live cells), whereas the absorbance from untreated control cells was defined as 100% live cells.

Morphological studies using normal inverted microscope

Treated cells were observed under anormal inverted microscope following 24h, 48h and 72h of incubation. The changes in cellular morphology due to death were examined and compared with untreated control. Photomicrographe were taken under the inverted microscope at 100× magnification.

Propidiumiodide staining

Propidium iodide fluorescence staining method was used to observe the apoptotic morphological changes in the treated cells. Both COLO205 cells and lymphocytes were treated with IC₅₀ concentrations of zerumbone and cisplatin for 24h. The untreated cells served as control. After incubation, cells were washed with PBS, fixed in absolute alcohol for 30min at 4 °C, rehydrated with PBS and incubated with 100µg propidium iodide (25µM) at 37 °C for 30min. Photomicrographs were taken under a fluorescent microscope at 200× magnification.

 Comet assay

DNA damage was assessed using the comet assay according to the method of Tice et al. [15]. 10 µl of the treated and untreated cells were suspended in 70 µl of 1% low melting agarose in PBS and were layered onto the slides pre-coated with 1% normal melting agarose. The slides were incubated at 4 °C for 30 min. A third layer was coated with 1% normal melting agarose and the slides were kept dry. After solidification, the slides were kept in cold lysis buffer (10mmol Tris, 2.5 M NaCl, 100 mmol EDTA, 1% N-lauroylsarcosine; pH 10) with fresh 1% Triton X-100 and 10% DMSO overnight at 4 °C.

For unwinding of the DNA, the slides were incubated in freshly prepared alkaline electrophoresis buffer (300 mmol NaOH, 1 mmol EDTA; pH 13) for 20 min. The DNA was electrophoresed at 25 V and 300 mA for 20 min at 4 °C. After electrophoresis, the slides were washed thrice with a neutralizing buffer (0.4 M Tris-HCl; pH 7.5), left to dry for 30 min and fixed in 75% ethanol for 10 min. After staining with 25 µM propidium iodide, comets from individual cells were examined using a fluorescence microscope. OPEN COMET software was used to score 50 comets for each experiment.

Statistical analysis

Values were expressed as the mean±standard deviation (SD), where n=5 for the MTT assay and n=3 for the comet assay. The values were subjected to analysis of variance (ANOVA) using GraphPad Prism software, Version 6.01 (California, USA). A statistically significant difference was considered to be present at P<0.05.

RESULTS AND DISCUSSION

Effect of zerumbone and cisplatin on cell growth

The antiproliferative effect of zerumbone and cisplatin on colorectal cancer cell line, COLO205 and normal human lymphocytes was determined by MTT assay. The growth of the cancer cells was inhibited in a dose (0-100µg/ml) and time (24h, 48h, 72h) dependent manner after exposure to zerumbone and cisplatin whereas lymphocytes were not affected after the exposure (fig.1).

Previous studies reported the growth inhibition property of zerumbone on human colon adenocarcinoma cell lines in a dose-dependent manner, while the growth of normal human dermal and colon fibroblast was minimally affected [16]. Our studies exhibited that zerumbone can induce cytotoxic effect on colon cancer cells in a dose as well as time-dependent manner.
Table 1: IC_{50} values of zerumbone and cisplatin on COLO205 cells for 24 h, 48 h and 72 h

| Compound   | IC_{50} (µg/ml) |
|------------|----------------|
|            | 24 h | 48 h | 72 h |
| Zerumbone  | 19   | 10   | 5    |
| Cisplatin  | 38   | 24   | 15   |

Effect of zerumbone and cisplatin on apoptotic cell death

COLO205 cells and lymphocytes were exposed to IC_{50} concentrations of zerumbone and cisplatin. The treated cancer cells demonstrated early signs of apoptosis such as membrane blebbing and cytoplasmic shrinkage (fig.2). The untreated COLO205 cells and treated lymphocytes showed a negligible change in the membrane morphology (fig. 2, 3). In the present study, it is proposed that zerumbone inhibits the cell proliferation by subsequent induction of apoptotic cell death of the colon cancer cells. This is clearly evident by the morphological changes in zerumbone-treated COLO205 cells that include distinctive nuclear morphology, chromatin condensation and fragmentation, loss of cell volume and production of apoptotic bodies (fig. 4), which are all features of apoptosis [19]. Several studies have exposed the apoptotic nature of zerumbone against various cancer cells, but it has an negligible effect on normal cells [3].

![Fig.2: Effect of zerumbone and cisplatin on COLO205 cells treated for 24 h](image)

![Fig.3: Effect of zerumbone and cisplatin on lymphocytes cells treated for 24 h](image)

Genotoxic effect of zerumbone and cisplatin on cancer cells and lymphocytes

Comet assay is a simple, rapid and reliable technique for the detection and quantification of DNA damage. The assay determines the extent of DNA damage in individual cells and this can be assessed from the length of DNA migration [15]. Comet assay was performed to analyse the extent of DNA damage caused by zerumbone and cisplatin against cancer cells and normal human lymphocytes. The tail length, % tail DNA and olive moment are considered as DNA damage parameters [20]. The zerumbone-treated COLO205 cells showed a significant DNA damage with the tail length of 85.61, percentage DNA in tail of 27.42 and olive moment of 25.14 when compared to the untreated control cells. The cisplatin-treated COLO205 cells also showed a significant DNA damage with the tail length of 69.36, percentage DNA in tail of 22.27 and olive moment of 18.38 when compared to the untreated control cells. In contrast, the treated lymphocytes did not demonstrate any obvious DNA damage when compared to the untreated lymphocytes. The zerumbonetreated lymphocytes illustrated tail length of 7.23, percentage DNA in tail of 6.88 and olive moment of 1.64. And the
ciplatin-treated lymphocytes illustrated tail length of 6.91, percentage DNA in tail of 6.23 and olive moment of 1.46 (fig 5; table 2). The genotoxic agents have the ability to interact with DNA and cause DNA damage. Our findings illustrated that zerumbone can cause DNA damage on colon cancer cells. Previous studies have evaluated the genotoxic effect of zerumbone as dose-dependent on Chinese hamster ovary cells and human peripheral blood lymphocytes. It has also reported that zerumbone is a cytotoxic but not a clastogenic substance in human lymphocytes [21, 22]. Zerumbone carried no obvious structural alerts and no particular mechanism had been identified such as nucleoside analogues that can cause genotoxic effect, making it necessary for further studies to better understand the molecular mechanisms of action of zerumbone. The present results provide an additional evidence that zerumbone has a genotoxic and cytotoxic effects on colorectal cancer cells, while subsidized effects were observed on human lymphocytes.

### Table 2: Effect of zerumbone and ciplatin on the extent of DNA damage on COLO205 and lymphocytes

| Concentration       | DNA damage | % Tail DNA | Olive moment |
|---------------------|------------|------------|--------------|
|                     | Tail length |            |              |
| COLO205             |            |            |              |
| Untreated Control   | 20.95±0.17  | 15.97±2.47 | 5.77±0.11    |
| Zerumbone (19 μg/ml)| 85.61±1.86  | 27.42±0.63 | 25.14±1.23   |
| Ciplatin (38 μg/ml) | 69.36±1.35  | 22.27±0.26 | 18.38±1.31   |
| Lymphocytes         |            |            |              |
| Untreated Control   | 1.77±0.17   | 1.94±0.11  | 0.57±0.04    |
| Zerumbone (19 μg/ml)| 7.23±0.65   | 6.88±0.46  | 1.64±0.21    |
| Ciplatin (38 μg/ml) | 6.91±0.21   | 6.23±0.11  | 1.46±0.11    |

The values are expressed in mean±SD, n=3, P<0.0001

### CONCLUSION

In the present study, zerumbone and ciplatin exhibited a potent antiproliferative activity against cancer cells, but with negligible effect on normal lymphocytes. Flow cytometric and genotoxic studies have revealed that zerumbone is a strong inducer of apoptosis and caused DNA damage in the cancer cells but with minor effect on lymphocytes. These findings have demonstrated that zerumbone can be a potential phytochemical to treat colon cancer. Further studies have to be carried out in animal models and clinical trials have to be conducted.

### ACKNOWLEDGEMENT

Rima Thiyam acknowledges financial support from DST Inspire Division, Department of Science and Technology, New Delhi, India in the form of DST Inspire Fellowship (IF120002, Grant No. DST/INSPIRE Fellowship/2012/70) to the present research work. The authors are grateful to Centre for Biotechnology, IST, JNTUH, Hyderabad for providing the laboratory facilities.

### AUTHORS CONTRIBUTION

The study was designed by RT and MLN, as the supervisor provided conceptual and technical guidance for all aspects of the project. RT performed the experimental work and assessed the data. The manuscript was prepared by RT and its critical revision was done by MLN. Final approval of the manuscript was made by RT and MLN.

### CONFLICTS OF INTEREST

There is not any conflict of interest which should be disclosed.

### REFERENCES

1. Rates SMK. Plants as source of drugs. Toxicon2011;1;39:603–13.
2. Churu G, Prakash D. Phytonutrients as therapeutic agents. J Complementary Integr Med 2014;11:151-69.
3. Murakami A, Takahashi D, Kinosita T, Koshimizu K, Kim HW, Yoshiiho Aet al. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppress free radical generation, pro-inflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the α, the β-unsaturated carbonyl group is a prerequisite. Carcinogenesis; 2002;23:795-402.
4. Kitayama T, Okamoto T, Hilit RK, Kawai Y, Takahashi S, Yonenori S et al. Chemistry of Zerumbone. 1. simplified isolation, conjugate addition reactions, and a unique ring contracting transannular reaction of its dibromide. J Org Chem 1999;64:2667-72.
5. Zakaria ZA, Mohamad AS, Cheer CT, Wong YY, Isra D, Sulaiman MR. Anti-inflammatory and anti nociceptive activities of Zingiberzerumbetmethanol extract in experimental model systems. Med Princ Pract 2010;19:287–94.
6. Habsah M, Amran M, Mackeen MM, Lajis NH, kikuzaki H, Nakatani Net al. Screening of Zingiberaceae extracts for antimicrobial and antioxidant activities. J Ethnopharmacol 2007;12:403–10.
7. Chandra K, Greane HM, Iam RR, Graham PJ. Antitumor activity of an extract of Zingiber from Hong Kong and its bioactive sesquiterpenoids Zerumbone. Nutr Cancer 2003;45:218-25.
8. Swagatika D, Monalisa R, Abtar M, Sajad S, Gopinath AK, Sanghamitra N, et al. Zerumbone, a natural plant dietary compound induces expression of interleukin-12p70 cytokine in human peripheral blood mononuclear cells. Asian J Pharm Clin Res 2016;9(Suppl3):312-5.
9. Sharifah Sakinah SA, Handayani ST, Azmah Ahmadia H, Wahiria L. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int 2007;7:4.
10. Supachai D, Bokyang S, Pornsarirott T, Bharat B. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res 2009;69:6581-9.
11. Rahman HS, Rasedee A, How CW, Abdul AB, Zeenathul NA, Othman HH, et al. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomed 2013;8:2769-81.
12. Celic M, Ural F, Yuzbasioğlu D, Ergun MA, Arslan O, Kasap R. In vitro effect of karathane LC (dinocap) on human lymphocytes. Mutagenesis 2005;20:101–4.
13. Duheji SJ, Ferie L, Jenkinson AM, E, Narayanam S. Crospreserved versus freshly isolated lymphocytes in human biomonitoring: endogenous and induced DNA damage, antioxidant status and repair capability. Mutagenesis 2002;17:211–4.
14. Houda S, Hayat T, Ibtisam T, Soua D, Abderraouf H. Evaluation of the genotoxicity of essential oil from Origanum compactum Benth. in human lymphocytes. Asian J Pharm Clin Res 2016;9(Suppl2):274-6.
15. Tico RR, Agurell E, Anderson D, Birlinson B, Hartmann A, Kobayashi H et al.Single-cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-21.
16. Murakami A, Tanaka T, Lee JY, Sury YH, Kim HW, Kawabata K, et al. ZER, a sesquiterpene in subgigron, suppresses skin tumor induction and promotion stages in ICR mice. Int J Cancer 2004;110:841-90.
17. Shukla Y, Singh M. Cancer preventive properties of ginger: a brief review. Food Chem Toxicol 2007;45:683–90.
18. Hoffman A, Spetner LM, Burke M. Redox-regulated mechanism may account for zerumbone's ability to suppress cancer-cell proliferation. Carcinogenesis 2002;23:1961.

19. O'Brien MA, Kirby R. Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care 2008;18:572–85.

20. Singh RK, Mishra SK, Kumar N, Singh AK. Assessment of DNA damage by comet assay in lymphocytes of workers occupationally exposed to petroleum fumes. Int J Genet 2010;2:18-22.

21. Adel SA, Ahmad BA, Syam MM. Evaluation of the genotoxicity of zerumbone in cultured human peripheral blood lymphocytes. Toxicol In Vitro 2010;24:707–12.

22. Adel SA. Genotoxicity assessment of a natural anti-cancer compound zerumbone on CHO cell lines. Int J Cancer Res 2012;8:119-29.